ArticleClinical cancer research : an official journal of the American Association for Cancer Research2020
First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer.
Open access · bronzeAbstract readClinical Trial, Phase I
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.8field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 31 citations in OpenAlex.
- Evolution of Hsp90 targeting: From stress biology to clinical translation.Cell stress & chaperones · 2026Review
- Targeting HSP90 in cancer: advances in the development of inhibitors, mechanisms of action, and therapeutic applications.Molecular cancer · 2026Review
- [EJNMMI radiopharmacy and chemistry · 2025Article
- In vivo imaging of heat shock protein 90: Diagnostic tool and support for Hsp90-targeted therapy.Cell stress & chaperones · 2025Review
- Radiosynthesis and Evaluation of [Journal of labelled compounds & radiopharmaceuticals · 2025Article
- Epichaperome-targeted myocardial imaging byClinical and translational imaging · 2024Article
- Review
- A novel PET probe to selectively image heat shock protein 90α/β isoforms in the brain.EJNMMI radiopharmacy and chemistry · 2024Article
- Review
- PU-H71 (NSC 750424): a molecular masterpiece that targets HSP90 in cancer and beyond.Frontiers in pharmacology · 2024Review
- Unraveling the Mechanism of Epichaperome Modulation by Zelavespib: Biochemical Insights on Target Occupancy and Extended Residence Time at the Site of Action.Biomedicines · 2023Article
- Article
- Radiosynthesis and preclinical evaluation of [EJNMMI radiopharmacy and chemistry · 2023Article
- HSP90-Specific nIR Probe Identifies Aggressive Prostate Cancers: Translation from Preclinical Models to a Human Phase I Study.Molecular cancer therapeutics · 2022Article
- The penalty of stress - Epichaperomes negatively reshaping the brain in neurodegenerative disorders.Journal of neurochemistry · 2021Review
- Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas.Cancer research · 2021Article
- Chemical tools for epichaperome-mediated interactome dysfunctions of the central nervous system.Nature communications · 2021Article
- Heat Shock Proteins in Lymphoma Immunotherapy.Frontiers in immunology · 2021Review
- The Unique Pharmacometrics of Small Molecule Therapeutic Drug Tracer Imaging for Clinical Oncology.Cancers · 2020Review
- Measuring Tumor Epichaperome Expression Using [JCO precision oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 2 institutions in 1 country.
Mark P S DunphyDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York. dunphym@mskcc.org.
Christina PresslLaboratory of Neural Systems, The Rockefeller University, New York, New York.ORCID 0000-0001-6108-2263
Nagavarakishore PillarsettyDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Milan GrkovskiDepartment of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-7228-9497
Shanu ModiDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-6427-7373
Komal JhaveriDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Larry NortonDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-3701-9250
Bradley J BeattieDepartment of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-9891-8271
Pat B ZanzonicoDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Danuta ZatorskaMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Tony TaldoneMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Stefan O OchianaMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Mohammad M UddinMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Eva M BurnaziRadiochemistry and Molecular Imaging Probes Core, Memorial Sloan Kettering Cancer Center, New York, New York.
Serge K LyashchenkoRadiochemistry and Molecular Imaging Probes Core, Memorial Sloan Kettering Cancer Center, New York, New York.
Clifford A HudisDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-7144-8791
Jacqueline BrombergDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Heiko M SchöderDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Josef J FoxDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Hanwen ZhangRadiochemistry and Molecular Imaging Probes Core, Memorial Sloan Kettering Cancer Center, New York, New York.
Gabriela ChiosisDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Jason S LewisDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-7065-4534
Steven M LarsonDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-6111-7507
Memorial Sloan Kettering Cancer Center · USRockefeller University · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MTranslating Stress Response Targeted Therapy for B-Cell LymphomasP50CA192937 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI DALLA-FAVERA, RICCARDO, ZELENETZ, ANDREW D. · 2016 to 2020
$10.9MLeveraging Pb-203/212 for the Theranostic Imaging and Therapy of Prostate CancerR35CA232130 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LEWIS, JASON S. · 2019 to 2025
$8.2MProject 3: Structural Basis for grp94 Drug Development and Chaperone FunctionP01CA186866 · NCI · OHIO STATE UNIVERSITY · PI GEWIRTH, DANIEL T · 2015 to 2019
$6.7MBiomarkers for predicting response to Hsp90 therapyR01CA172546 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHIOSIS, GABRIELA, DUNPHY, MARK P. · 2013 to 2017
$2.9MA chemical chaperomics platform for ADR56AG061869 · NIA · SLOAN-KETTERING INST CAN RESEARCH · PI CHIOSIS, GABRIELA · 2018 to 2019
$1.8MFirst Human Trial of Src/Abl-Targeted PET Tumor Imaging with F-18 SKI-249380R21CA167803 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI DUNPHY, MARK P. · 2012 to 2013
$736kBiomarkers of response to Hsp90 inhibitors in triple-negative breast cancerR21CA158609 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHIOSIS, GABRIELA · 2012 to 2013
$426kNCI NIH HHS L30 CA199352NCI NIH HHS P01 CA186866NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA192937NCI NIH HHS R01 CA172546NCI NIH HHS R21 CA158609NCI NIH HHS R21 CA167803NCI NIH HHS R35 CA232130NIA NIH HHS R56 AG061869
Abstract
purposeEXPERIMENTAL
designAdult patients with cancer (
results
conclusionsOur first-in-human results demonstrate the safety and feasibility of noninvasive
Indexed as
AdultAgedBenzodioxolesCell Line, TumorCell ProliferationFemaleHSP90 Heat-Shock ProteinsHumansIodine RadioisotopesMaleMiddle AgedNeoplasmsPositron Emission Tomography Computed TomographyPurinesTissue Distribution9H-purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-N-(1-methylethyl)-BenzodioxolesHSP90 Heat-Shock ProteinsIodine-124Iodine RadioisotopesPurines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.